InMed Pharmaceuticals Inc
NASDAQ:INM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
InMed Pharmaceuticals Inc
Accrued Liabilities
InMed Pharmaceuticals Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
InMed Pharmaceuticals Inc
NASDAQ:INM
|
Accrued Liabilities
$1.1m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
69%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Accrued Liabilities
$3.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-1%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Accrued Liabilities
CA$43.8m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Accrued Liabilities
$36.5m
|
CAGR 3-Years
16%
|
CAGR 5-Years
95%
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Accrued Liabilities
$19m
|
CAGR 3-Years
36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
InMed Pharmaceuticals Inc
Glance View
InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The firm is developing a pipeline of prescription-based products targeting treatments for diseases with unmet medical needs as well as developing manufacturing technologies. The company is specializing in the research and development of cannabinoid-based therapies and a system for the manufacturing of pharmaceutical-grade cannabinoids. The company is also developing an integrated biosynthesis-based manufacturing approach, called IntegraSyn, for synthesizing pharmaceutical-grade cannabinoids, for potential use in product candidates. The firm's two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 provides direct neuroprotection and reduce intraocular pressure in the eye.
See Also
What is InMed Pharmaceuticals Inc's Accrued Liabilities?
Accrued Liabilities
1.1m
USD
Based on the financial report for Dec 31, 2025, InMed Pharmaceuticals Inc's Accrued Liabilities amounts to 1.1m USD.
What is InMed Pharmaceuticals Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
69%
Over the last year, the Accrued Liabilities growth was -8%. The average annual Accrued Liabilities growth rates for InMed Pharmaceuticals Inc have been -12% over the past three years , 69% over the past five years .
